Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Loxenatide

Stage Phase 2/3Stale

Route injection

Sources

registry, as of 2026-03-13Stale

https://clinicaltrials.gov/study/NCT05172999

Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia. Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Fudan University. Enrollment 30. Conditions Atypical Endometrial Hyperplasia; Obesity; Fertility Issues. To study if polyethylene glycol loxenatide plus levonorgestrel-releasing intrauterine system (LNG-IUS) will improve response rates in patients with endometrial atypical hyperplasia.

ClinicalTrials.gov NCT05172999 protocol and results modules

Studies

Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia

Registry NCT05172999

Phase Phase 2/3

Status Completed

Enrollment 30

Start 2022-01-08

Primary completion 2025-12-30

Study completion 2026-02-28

Catalyst Primary completion. 2025-12-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

LNG-IUS

Population Atypical Endometrial Hyperplasia; Obesity; Fertility Issues

LOX+LNG-IUS

Population Atypical Endometrial Hyperplasia; Obesity; Fertility Issues